JP Morgan Maintains Neutral on Halozyme Therapeutics, Raises Price Target to $79
Benzinga Newsdesk 20 hours ago
Analyst RatingsNewsPrice Target
JP Morgan analyst Jessica Fye maintains Halozyme Therapeutics (NASDAQ:HALO) with a Neutral and raises the price target from $78 to $79.
JP Morgan analyst Jessica Fye maintains Halozyme Therapeutics (NASDAQ:HALO) with a Neutral and raises the price target from $78 to $79.